vassiki sanogo to Cost-Benefit Analysis
This is a "connection" page, showing publications vassiki sanogo has written about Cost-Benefit Analysis.
Connection Strength
0.428
-
Sanogo V, Saud Almutairi RD, Diaby V. Budget impact of lecanemab for medicare beneficiaries with early Alzheimer's disease in the United States: a subgroup analysis. Expert Rev Pharmacoecon Outcomes Res. 2025 Dec; 25(10):1421-1426.
Score: 0.216
-
Diaby V, Tawk R, Sanogo V, Xiao H, Montero AJ. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat. 2015 May; 151(1):27-40.
Score: 0.107
-
Diaby V, Pandey S, Sanogo V, Dhayan Almutairi R, Kanoria Y, Nag SS. Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States. J Manag Care Spec Pharm. 2025 Jan; 31(1):53-59.
Score: 0.053
-
Diaby V, Pandey S, Sanogo V, Almutairi RD, Kanoria Y, Nag SS. Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States. J Manag Care Spec Pharm. 2025 Jan; 31(1):60-67.
Score: 0.053